Vaccinex, Inc. (VCNX)
OTCMKTS · Delayed Price · Currency is USD
0.7001
-0.2999 (-29.99%)
At close: Oct 20, 2026
Vaccinex Revenue
In the year 2024, Vaccinex had annual revenue of $601.00K with 5.44% growth. Vaccinex had revenue of $213.00K in the quarter ending December 31, 2024. That makes Vaccinex the 44,296th largest company in the world by revenue and 6,279th in the United States.
Revenue
601.00K
Revenue Growth
+5.44%
P/S Ratio
3.12
Revenue / Employee
24.04K
Employees
27
Market Cap
1.87M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 601.00K | 31.00K | 5.44% |
| Dec 31, 2023 | 570.00K | 295.00K | 107.27% |
| Dec 31, 2022 | 275.00K | -625.00K | -69.44% |
| Dec 31, 2021 | 900.00K | 275.00K | 44.00% |
| Dec 31, 2020 | 625.00K | 102.00K | 19.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CASI Pharmaceuticals | 20.11M |
| International Stem Cell | 9.51M |
| BioAtla | 8.50M |
| Pacific Software | 2.40M |
| GPL Holdings | 376.54K |
| Enzolytics | 46.59K |
| Affymax | 42.00K |
Vaccinex News
- 14 days ago - SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study - GlobeNewsWire
- 3 months ago - Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026 - GlobeNewsWire
- 5 months ago - Vaccinex Reports 2025 Annual Financial Results - GlobeNewsWire
- 10 months ago - Vaccinex announces $60M revenue sharing agreement with PDV - TheFly
- 1 year ago - Vaccinex to reports new clinical results on pepinemab at ASCO meeting - TheFly
- 1 year ago - Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting - GlobeNewsWire
- 1 year ago - Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy - TheFly
- 1 year ago - Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - GlobeNewsWire